Meng K Wong1, Cedric C Y Ng2, Chik H Kuick3, Sze J Aw3,4, Vikneswari Rajasegaran2, Jing Q Lim2, Jain Sudhanshi3, Eva Loh3, Minzhi Yin5, Jing Ma5, Zhongde Zhang5, Prasad Iyer6, Amos H P Loh1,7,8, Derrick W Q Lian3,8, Shi Wang9, Shaun G H Goh9, Tse H Lim10, Alvin S T Lim10, Tony Ng11, Angela Goytain11, Alwin H L Loh4,8, Puay H Tan4,8, Bin T Teh2,8, Kenneth T E Chang1,3,8. 1. VIVA-KKH Paediatric Brain and Solid Tumour Laboratory, KK Women's and Children's Hospital, Singapore. 2. Laboratory of Cancer Epigenome, National Cancer Centre, Singapore. 3. Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore. 4. Department of Anatomical Pathology, Singapore General Hospital, Singapore. 5. Department of Pathology, Shanghai Children's Medical Centre, Shanghai, China. 6. Paediatric Haematology-Oncology Service, Singapore. 7. Department of Paediatric Surgery, KK Women's and Children's Hospital, Singapore. 8. Duke-NUS Medical School, Singapore. 9. Department of Pathology, National University Health System, Singapore. 10. Department of Molecular Pathology, Singapore General Hospital, Singapore. 11. Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
AIMS: Clear cell sarcoma of the kidney (CCSK) is a rare paediatric renal malignant tumour. The majority of CCSKs have internal tandem duplications (ITDs) of the BCOR gene, whereas a minority have the YWHAE-NUTM2 gene fusion. A third 'double-negative' (DN) category comprises CCSKs with neither BCOR ITDs nor YWHAE-NUTM2 fusion. The aim of this study was to characterise 11 histologically diagnosed CCSKs immunohistochemically (with CCND1, BCOR and CCNB3 stains) and genetically. METHODS AND RESULTS: By next-generation sequencing, 10 cases (90.9%) had BCOR exon 15 ITDs, with positive BCOR immunoreactivity being found in four (36%) or eight (72%) cases, depending on the antibody clone. By reverse transcription polymerase chain reaction, none had the YWHAE-NUTM2 fusion. The DN case had a BCOR-CCNB3 fusion and strong nuclear CCNB3 and BCOR immunoreactivity. Quantitative polymerase chain reaction showed markedly elevated BCOR expression in this case, whereas BCOR ITD cases had lower levels of elevated BCOR expression. CONCLUSIONS: The majority of the CCSKs in our cohort had BCOR ITDs, and none had the YWHAE-NUTM2 fusion. We verified the strong, diffuse cyclin D1 (CCND1) immunoreactivity in CCSKs described in recent reports. BCOR immunoreactivity was not consistently positive in all CCSKs with BCOR ITDs, and therefore cannot be used as a diagnostic immunohistochemical stain to identify BCOR ITD cases. The DN case was a BCOR-CCNB3 fusion sarcoma. BCOR-CCNB3 sarcoma is typically a primary bone sarcoma affecting male adolescents, and this is the first report of it presenting in a kidney of a young child as a CCSK. The full spectrum of DN CCSKs awaits more comprehensive characterisation.
AIMS: Clear cell sarcoma of the kidney (CCSK) is a rare paediatric renal malignant tumour. The majority of CCSKs have internal tandem duplications (ITDs) of the BCOR gene, whereas a minority have the YWHAE-NUTM2 gene fusion. A third 'double-negative' (DN) category comprises CCSKs with neither BCOR ITDs nor YWHAE-NUTM2 fusion. The aim of this study was to characterise 11 histologically diagnosed CCSKs immunohistochemically (with CCND1, BCOR and CCNB3 stains) and genetically. METHODS AND RESULTS: By next-generation sequencing, 10 cases (90.9%) had BCOR exon 15 ITDs, with positive BCOR immunoreactivity being found in four (36%) or eight (72%) cases, depending on the antibody clone. By reverse transcription polymerase chain reaction, none had the YWHAE-NUTM2 fusion. The DN case had a BCOR-CCNB3 fusion and strong nuclear CCNB3 and BCOR immunoreactivity. Quantitative polymerase chain reaction showed markedly elevated BCOR expression in this case, whereas BCOR ITD cases had lower levels of elevated BCOR expression. CONCLUSIONS: The majority of the CCSKs in our cohort had BCOR ITDs, and none had the YWHAE-NUTM2 fusion. We verified the strong, diffuse cyclin D1 (CCND1) immunoreactivity in CCSKs described in recent reports. BCOR immunoreactivity was not consistently positive in all CCSKs with BCOR ITDs, and therefore cannot be used as a diagnostic immunohistochemical stain to identify BCOR ITD cases. The DN case was a BCOR-CCNB3 fusion sarcoma. BCOR-CCNB3sarcoma is typically a primary bone sarcoma affecting male adolescents, and this is the first report of it presenting in a kidney of a young child as a CCSK. The full spectrum of DN CCSKs awaits more comprehensive characterisation.
Authors: Pedram Argani; Bruce Pawel; Sara Szabo; Miguel Reyes-Múgica; Charles Timmons; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2018-08 Impact factor: 6.394
Authors: Pedram Argani; Yu-Chien Kao; Lei Zhang; Carlos Bacchi; Andres Matoso; Rita Alaggio; Jonathan I Epstein; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2017-12 Impact factor: 6.394
Authors: Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota Journal: Hum Pathol Date: 2019-01-08 Impact factor: 3.466
Authors: Li Lei; Bradley A Stohr; Stacey Berry; Christina M Lockwood; Jessica L Davis; Erin R Rudzinski; Christian A Kunder Journal: Pract Lab Med Date: 2020-05-16
Authors: Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda Journal: Cancer Lett Date: 2020-11-25 Impact factor: 9.756